Publications by authors named "O Beyne-Rauzy"
Article Synopsis
- Systemic inflammatory and autoimmune diseases (SIADs) affect 10-20% of patients with myelodysplastic syndrome (MDS), with VEXAS syndrome being a newly identified condition linked to specific genetic mutations.
- This study aimed to analyze myeloid immune cell types (dendritic cells and monocytes) in MDS patients with and without SIADs, revealing significant reductions in these cells in those with SIADs, particularly in those with VEXAS syndrome.
- The findings suggest potential causes for the decreased immune cell counts, including movement to areas of inflammation, increased cell death, or issues with cell formation in the bone marrow.
Venous thromboembolism during systemic inflammatory and autoimmune diseases associated with myelodysplastic syndromes, chronic myelomonocytic leukaemia and myelodysplastic/myeloproliferative neoplasms: a French multicentre retrospective case-control study.
Clin Exp Rheumatol
July 2022
Objectives: Myelodysplastic syndromes (MDS) and chronic myelomonocytic leukaemia (CMML) are associated with systemic inflammatory and autoimmune diseases (SIADs) in 10-30% of cases. The aims of this study were (i) to evaluate the prevalence of venous thromboembolism VTE in patients presenting with both MDS/CMML and SIADs, (ii) to describe risk factors associated with thrombosis, and (iii) to analyse the impact of VTE on overall survival and transformation to acute myeloid leukaemia in comparison to patients with MDS/CMML-associated SIADs without VTE.
Methods: This retrospective multicentre case-control study was conducted among patients with MDS/CMML and dysimmune disorders and featured in the French retrospective database of the French Network of Dysimmune Disorders Associated with Hemopathies (MINHEMON), diagnosed with MDS/CMML and dysimmune disorders.
In order to improve the outcome observed with azacitidine (AZA) in higher-risk Myelodysplastic syndrome (MDS), its combination with other drugs in MDS must be evaluated. So far, no combination has not been shown to be more effective than AZA alone. AZA-PLUS was a phase II trial that, in a "pick a winner" approach, randomly assigned patients with higher-risk MDS, CMML and low blast count AML to: AZA; AZA plus lenalidomide; AZA plus Valproic Acid or AZA plus Idarubicin.
View Article and Find Full Text PDFBackground: The general practitioner (GP) is central to managing patients with cancer, whose numbers are increasing worldwide. The GP's involvement requires better coordination between involved partners, in particular oncologists and GPs.
Objectives: To conduct a feasibility study of remote participation of GPs in multi-disciplinary consultation meetings (MCMs).